Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Harmony Biosciences (Nasdaq: HRMY) will announce its fourth quarter and full year 2021 financial results on February 28, 2022. A conference call will follow at 8:30 a.m. ET. Investors can participate by dialing (833) 614-1471 domestically or +1 (914) 987-7209 internationally, using passcode 7277008. A replay of the call will be available within 24 hours. Harmony Biosciences focuses on innovative treatments for rare neurological diseases. For more information, visit their website.

Positive

• Upcoming financial results could showcase growth metrics.
• Potential for increased investor interest due to the conference call.

Negative

• None.

PLYMOUTH MEETING, Pa., Feb. 14, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's fourth quarter and full year 2021 financial results on Monday, February 28, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.

To participate in the call, please dial (833) 614-1471 (domestic) or +1 (914) 987-7209 (international), and reference passcode 7277008. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replayed webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

A replay of the call will be available within 24 hours by dialing (855) 859-2056 (domestic) or +1 (404) 537-3406 (international) and entering conference ID: 7277008. The replay will be available until March 7, 2022.

About Harmony Biosciences 
Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare neurological diseases who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

Harmony Biosciences Media Contact: 
Nancy Leone 
215-891-6046 
nleone@harmonybiosciences.com 

Harmony Biosciences Investor Contact:
Patti Bank
ICR Westwicke
415-513-1284
ir@harmonybiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-announces-date-of-fourth-quarter-and-full-year-2021-financial-results-301479276.html

SOURCE Harmony Biosciences

FAQ

When will Harmony Biosciences release its Q4 2021 results?

Harmony Biosciences will release its Q4 2021 financial results on February 28, 2022.

What time is the Harmony Biosciences conference call scheduled?

The conference call is scheduled for 8:30 a.m. ET on February 28, 2022.

How can I participate in Harmony Biosciences' conference call?

You can participate by dialing (833) 614-1471 domestically or +1 (914) 987-7209 internationally and referencing passcode 7277008.

Is there a way to listen to a replay of the conference call?

Yes, a replay will be available within 24 hours by dialing (855) 859-2056 domestically or +1 (404) 537-3406 internationally.

What is Harmony Biosciences' focus as a pharmaceutical company?

Harmony Biosciences focuses on developing innovative therapies for patients with rare neurological diseases.